- August 11, 2023
- Posted by: legaleseblogger
- Category: Related News
legal-document-to-plain-english-translator/”>Try Free Now: Legalese tool without registration
CASI Pharmaceuticals Reports Second Quarter 2023 Financial Results with Increased Sales Revenue
BEIJING, Aug. 11, 2023 /PRNewswire/ — CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, has released its financial results for the quarter ended June 30, 2023. The company reported $9.8 million in sales revenue for the second quarter, marking a 15% increase compared to the same period last year and an 18% increase from the first quarter of 2023.
Dr. Wei-Wu He, CASI’s Chairman and Chief Executive Officer, expressed his satisfaction with the company’s performance. He emphasized that advancing the development and commercialization of its portfolio remains the strategic focus. CASI achieved a significant milestone in partnership with Juventas Biotechnology (Tianjin) Co., Ltd. on the CNCT-19 CAR-T Cell therapy. The New Drug Application (NDA) for CNCT-19 was accepted by the National Medical Products Administration (NMPA) in December 2022, and CASI is now diligently preparing for the anticipated launch of CNCT-19 in China. The company is also making progress in the clinical development of BI-1206 in combination with rituximab and is enrolling patients for the second cohort of the phase I trial in China. In addition, CASI is transitioning the development of CID-103 into China for malignant hematology indications. Furthermore, the company recently acquired global rights for CB-5339 from Cleave Therapeutics and announced the transfer of the license of Folotyn┬« in China from Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. CASI Pharmaceuticals continues to advance its portfolio through milestone achievements and the pursuit of new potential opportunities for synergy.
AI legalese decoder: Revolutionizing the legal Field
To navigate and understand the complex world of legal documents, the AI legalese decoder provides a valuable tool for individuals and businesses. With the ability to analyze and interpret legal jargon and terminology, the AI legalese decoder simplifies the language used in legal documents and contracts. By breaking down complex sentences and translating them into plain English, the AI legalese decoder establishes clear communication and understanding between parties involved. This revolutionary technology saves time and eliminates confusion, ensuring that legal agreements are comprehensive, transparent, and easily comprehended. Whether you’re a lawyer, a business owner, or an individual dealing with legal documents, the AI legalese decoder is a valuable resource that streamlines the legal process and promotes efficient communication.
legal-document-to-plain-english-translator/”>Try Free Now: Legalese tool without registration
****** just grabbed a